Previous case-control studies showed that genetic variation in the fibrinogen γ gene (FGG) increased the risk for deep vein thrombosis (VT) in adults. We investigated the association between the fibrinogen α (FGA) and FGG haplotypes, the factor VLeiden-mutation, and pediatric VT and thromboembolic stroke (TS) in 2 independent study samples. Association analysis revealed that the FGA-H1 and FGG-H2 haplotypes were significantly overtransmitted to VT patients (FGA-H1, P = .05; FGG: H2, P = .032). In contrast, the FGG-H3 haplotype was undertransmitted (P = .022). In an independent study sample, FGA-H1 (P = .008) and FGG-H2 (P = .05) were significantly associated with TS. The association of FGA and FGG haplotypes with VT was more pronounced in FVLeiden-negative families (FGA-H1, P = .001; FGG-H2, P = .001), indicating a genetic interaction between both risk factors. The risk-conferring FGG-H2 and the protective FGG-H3 haplotypes correlated with low (FGG-H2) and high (FGG-H3) levels of the γ′ chain variant, respectively. These results provide independent and novel evidence that FGA-H1 and FGG-H2 variants are associated with an increased risk of VT and TS in children. The observed negative correlation of genetic VT risk with the plasma levels of the fibrinogen γ′ variant suggests that FGG-H2 and -H3 haplotypes modify thrombosis risk by controlling the level of this FGG splice isoform.

Population-based association studies in adults have provided sound evidence for the association of fibrinogen levels with arterial disease, and for the association of fibrinogen gene variations with fibrinogen levels. For example, abnormalities of fibrinogen levels have been reported to affect risk for deep vein thrombosis (VT), particularly in the elderly.1,2  However, evidence for the association of disease and fibrinogen gene polymorphisms thought to affect fibrinogen levels is weak.3,4  One of the mechanisms by which changes in the fibrin network may contribute to an increased VT risk may hinge on the composition of circulating total fibrinogen levels, particularly the fraction of fibrinogen γ′ levels, which in part is influenced by genetic variants residing in the fibrinogen gamma (FGG) gene located on the long arm of human chromosome 4 (4q28). A recent study investigating the role of genetic variants in predisposing to VT implicated genetic variants in fibrinogen alpha (FGA) and FGG genes as genetic determinants for VT through the reduction of circulating plasma fibrinogen γ′ levels.5  In this study, homozygous carriership of an FGG risk haplotype (FGG-H2) was associated with an increased risk for VT (odds ratio = 2.4; 95% confidence interval, 1.5-3.9) and, furthermore, reduced fibrinogen γ′ levels and reduced ratios of fibrinogen γ′ to total fibrinogen. This study was further corroborated by a recent study by Grünbacher et al,6  which showed an increased risk for carriers of the FGG 10034 TT genotype and VT (odds ratio = 2.01; 95% confidence interval, 1.23-3.31, P = .006) in 358 patients and 783 controls, further supporting the importance of genetic variants in FGG in the pathogenesis of VT. However, similar studies in VT of pediatric onset are lacking. VT in children is a rare event that probably occurs in neonates and children with underlying conditions, such as cancer, sepsis, autoimmune disease, and congenital heart disease, or as a consequence of invasive therapeutic procedures. Prominent complicating features of VT in children include lack of thrombus resolution and development of postthrombotic syndrome.7,9  Because of the low incidence of pediatric VT in the general population (0.07-0.14/10 000 population children; ∼ 5/10 000 hospital admissions of children), studies addressing the impact of genetic modifiers of thrombosis on the incidence of pediatric VT are limited by the relatively small number of patients and therefore often remain inconclusive. Meta-analyses of available data suggest that inherited thrombophilic mutations in coagulation factors identified in adult patients (ie, factor VLeiden [FVLeiden] G1691A, prothrombin G20210A, deficiency of protein S, protein C, and antithrombin) are also the most common genetic determinants of pediatric first VT and ischemic stroke.7,9,10  The contribution of fibrinogen gene variation to the incidence of VT in children, and the association with the relative abundance of fibrinogen γ chain isoforms in plasma is unknown. The goal of the current study was to examine the association between genetic variation in FGG and FGA genes, plasma levels of γA/γ′ fibrinogen, and thromboembolic disease (VT and nonvascular thromboembolic stroke [TS]) in children.

In the German study center Muenster, plasma and DNA samples of 244 families of children with VT (Figure 1) and 268 families of children with nonvascular TS (replication cohort),11  that is, samples of the propositus, nonaffected brothers or sisters, and biologic parents, were collected between January 2002 and December 2007. The present study was performed in accordance with the ethical standards laid down in the updated version of the 1964 Declaration of Helsinki and was approved by the medical ethics committee of the University of Münster, Germany. With written parental consent, term neonates and children with confirmed diagnosis of VT not older than 18 years at onset, biologic brothers and sisters, and available parents were enrolled. Premature birth (≤ 36 gestational weeks), patients older than 18 years at onset, and children with a first ischemic stroke of vascular origin were excluded. In addition, children with missing parents, families with nonpaternity, children lost to follow-up, and patients without parental consent were excluded. Additional exclusion criteria were ongoing liver, renal, or inflammatory diseases, malignancies, and concurrent treatment regimens known to influence fibrinogen levels. Inclusion and exclusion criteria are shown in Figure 1. The replication study sample with pediatric TS and criteria for group assignment to vascular stroke were described in detail elsewhere.11,12 

Figure 1

Flow chart of patient-parent trio selection. Inclusion and exclusion criteria for patients enrolled in the study are shown.

Figure 1

Flow chart of patient-parent trio selection. Inclusion and exclusion criteria for patients enrolled in the study are shown.

Close modal

Blood sample collection

Blood sample collection from patients was done in the morning after a 12-hour fasting period (infants fasted 4-6 hours); samples were drawn by peripheral venipuncture into plastic tubes containing one-tenth by volume of 3.8% trisodium citrate (Sarstedt) and were immediately placed on melting ice. The blood samples from patients were collected 6 to 12 months after the acute thrombotic event and at least 6 weeks apart from anticoagulation. Platelet-poor plasma was prepared by centrifugation at 3000g and 4°C for 2 × 20 minutes, aliquoted in polystyrene tubes, stored at −70°C, and thawed immediately before assay. DNA extraction was performed by a spin column procedure (QIAGEN) according to the manufacturer's instructions.

Fibrinogen and fibrinogen gamma γ′ antigen measurements

Total fibrinogen was determined according to the Clauss method using Dade thrombin reagent (Dade-Behring). The test was performed on a Dade Behring BCS analyzer. Fibrinogen γ′ antigen levels were measured by enzyme-linked immunosorbent assay as described previously13  with the following modifications: Fibrinogen gamma′ chains were detected with the L2B antibody that recognizes both the full-length as well as the truncated form of the γ′ chain variant. Standards were prepared from admixtures of purified peak I and II preparations of fibrinogen corresponding to a range between 2% and 20% gamma′ content, and all patient samples fell into this concentration range. Horseradish peroxidase-labeled L2B-antibody binding to immobilized patient fibrinogen was calculated from the Vmax of color development over 15 minutes.

Genetic analysis

We identified 7 haplotype tagging single nucleotide polymorphisms (htSNPs) capturing 97.5% of the genetic variation in FGG and FGA genes using the genotype information from Centre d'Etude du Polymorphisme Humain families available from HAPMAP (www.hapmap.org) and the SNPtagger-tool as implemented in HAPLOVIEW.14  These htSNPs are composed of 3 SNPs located in FGG (rs2066860, rs2066861, rs1049636) and 4 SNPs in FGA (rs2070011, rs2070014, rs2070016, rs6050; Thr312Ala), and are in accordance with the htSNPs recently reported by Kardys et al.4  Genotyping was performed using the TaqMan allelic discrimination method on a 384-well H7900 (Applied Biosystems) using 2 ng of genomic DNA. For quality control, each plate contained 8 positive Centre d'Etude du Polymorphisme Humain controls and 8 no-template controls to ensure genotyping accuracy. Genotyping efficiency was more than 99.5%. In addition, the presence or absence of the FVLeiden mutation was determined using standard laboratory techniques.15,16 

Statistical analysis

Hardy-Weinberg equilibrium for each htSNP was tested using χ2 analysis across all samples. Family-based association was determined using the transmission disequilibrium test (TDT)17  in 244 trios comprising unaffected parents and the affected child; haplotypes were inferred using the Expectation Maximization Algorithm as implemented in Haploview (Version 4.0).14  Significance of association was assessed using a Pearson χ2 test and corrected for multiple testing using 10 000 permutations as implemented in Haploview. TDT analyses were repeated after stratification for presence of at least one copy of the FVLeiden mutation in the affected child (46 families positive for the FVLeiden mutation, 198 families without FVLeiden). For correlation analyses between associated FGG haplotypes and fibrinogen γ′ to total fibrinogen levels in the affected children, the individual haplotypes were reconstructed based on phase because genotype information was available for both parents and the affected child. Distribution of total fibrinogen and fibrinogen γ′ levels were assessed using the Kolmogorov-Smirnov test for normalcy to ensure a normal distribution as a prerequisite for parametric analyses. Correlation analyses were performed using one-way analysis of variance, followed by the appropriate post hoc test (Student t test). P values were adjusted for multiple testing using the Bonferroni method (haplotypes, FVLeiden carriership [yes/no], 2 phenotypes = 8 comparisons).

Association between fibrinogen haplotypes and pediatric VT

Genotyping of 244 families for VT (786 persons) showed that the selected 7 htSNPs identified the 4 most common haplotypes in FGG and the 5 most common haplotypes in FGA, and thus captures 97.5% of the genetic variation present in haplotypes at a frequency more than 1% (Figure 2A). For all SNPs, the distribution of the genotypes was in Hardy-Weinberg equilibrium and similar to those reported by previous studies.4,5  Consistent with previous observations,4,5  a high degree of linkage disequilibrium was detected between FGA and FGG (Figure 2B). However, in our study, recombination events were detected between rs2070011 and rs1049636 (D′ = 0.1) that may affect haplotype structure of the fibrinogen gene cluster (Figure 2A).

Figure 2

LD structure and haplotypes in FGA and FGG genes. (A) Five FGA (H1-H5) and 4 FGG (H1-H4) haplotypes are defined by 7 htSNPs capturing 97.5% of the genetic variation in the extended linkage disequilibrium (LD) block harboring FGA and FGG. (B) LD structure underlying FGA and FGG.

Figure 2

LD structure and haplotypes in FGA and FGG genes. (A) Five FGA (H1-H5) and 4 FGG (H1-H4) haplotypes are defined by 7 htSNPs capturing 97.5% of the genetic variation in the extended linkage disequilibrium (LD) block harboring FGA and FGG. (B) LD structure underlying FGA and FGG.

Close modal

Single-point TDT identified 3 significantly associated SNPs with VT, rs6050 [Thr312Ala] (ratio of transmissions to nontransmissions of the overtransmitted allele [T:U] 84:51, χ2 = 8.067, P = .004), rs2070011 (T:U 102:64, χ2 = 8.699, P = .003) in FGA, and rs2066861 (T:U 80:52, χ2 = 5.939, P = .015) in FGG (Table 1). For each SNP, a significant overtransmission to affected offspring was observed, implying that these SNPs confer a risk for juvenile VT. Subsequent haplotype association analysis revealed that haplotype H1 of the FGA gene (AACT) and haplotypes H2 (ATC) were overtransmitted to VT patients, whereas H3 (GCC) of the FGG gene was significantly undertransmitted to VT patients (FGA: H1, T:U 60:32.6, χ2 = 9.134, P = .05; FGG: H2, T:U 85:47, χ2 = 10.939, P = .032; H3, T:U 28:48, χ2 = 5.277, P = .022; Table 2). The associations for H1 in FGA and H3 in FGG remained significant after permutation testing using 10 000 permutations (FGA: H1, χ2 = 9.137, P = .024; FGG: H3, χ2 = 8.523, P = .037). These data document that the FGA-H1 and the FGG-H2 haplotypes are overrepresented in pediatric patients with VT. Conversely, the FGG-H3 haplotype was significantly undertransmitted to affected offspring in our pediatric VT cohort and might thus represent a protective haplotype.

Table 1

Single-point association (TDT) between variants in FGA and FGG and juvenile VT

SNP ID no.MAFOvertransmittedT:Uχ2P
All VT      
    rs6050 0.319 84:51 8.067 .004* 
    rs2070016 0.148 42:41 0.012 .913 
    rs2070014 0.154 46:31 2.922 .087 
    rs2070011 0.419 102:64 8.699 .003* 
    rs1049636 0.252 62:52 0.877 .349 
    rs2066861 0.317 80:52 5.939 .015* 
    rs2066860 0.048 15:10 .317 
FVLeiden-negative families      
    rs6050 0.315 68:38 8.491 .004* 
    rs2070016 0.142 33:30 0.143 .705 
    rs2070014 0.162 38:26 2.25 .134 
    rs2070011 0.41 85:47 10.939 .001* 
    rs1049636 0.257 50:47 0.093 .761 
    rs2066861 0.321 68:40 7.259 .007* 
    rs2066860 0.048 12:08 0.8 .371 
FVLeiden-positive families      
    rs6050 0.325 16:11 0.926 .336 
    rs2070016 0.171 11:08 0.474 .491 
    rs2070014 0.128 08:04 1.333 .248 
    rs2070011 0.442 17:15 0.125 .724 
    rs1049636 0.237 12:04 .045 
    rs2066861 0.295 12:10 0.182 .670 
    rs2066860 0.045 03:02 0.2 .655 
SNP ID no.MAFOvertransmittedT:Uχ2P
All VT      
    rs6050 0.319 84:51 8.067 .004* 
    rs2070016 0.148 42:41 0.012 .913 
    rs2070014 0.154 46:31 2.922 .087 
    rs2070011 0.419 102:64 8.699 .003* 
    rs1049636 0.252 62:52 0.877 .349 
    rs2066861 0.317 80:52 5.939 .015* 
    rs2066860 0.048 15:10 .317 
FVLeiden-negative families      
    rs6050 0.315 68:38 8.491 .004* 
    rs2070016 0.142 33:30 0.143 .705 
    rs2070014 0.162 38:26 2.25 .134 
    rs2070011 0.41 85:47 10.939 .001* 
    rs1049636 0.257 50:47 0.093 .761 
    rs2066861 0.321 68:40 7.259 .007* 
    rs2066860 0.048 12:08 0.8 .371 
FVLeiden-positive families      
    rs6050 0.325 16:11 0.926 .336 
    rs2070016 0.171 11:08 0.474 .491 
    rs2070014 0.128 08:04 1.333 .248 
    rs2070011 0.442 17:15 0.125 .724 
    rs1049636 0.237 12:04 .045 
    rs2066861 0.295 12:10 0.182 .670 
    rs2066860 0.045 03:02 0.2 .655 

MAF indicates minor allele frequency; and T:U, ratio of transmissions to nontransmissions.

*

P value indicates statistical significance.

Table 2

Association between FGA and FGG haplotypes and juvenile VT

BlockHaplotype*FrequencyT:U*χ2P
All VT      
    FGA haplotypes      
        H1 AACT 0.324 62.0: 32.6 9.134 .002 
        H2 GACC 0.28 39.7: 51.7 1.576 .209 
        H3 GATC 0.145 17.0: 32.0 4.591 .0321 
        H4 GGCC 0.138 27.3: 23.3 0.317 .574 
        H5 GACT 0.102 19.0: 22.4 0.278 .598 
    FGG haplotypes      
        H1 ACC 0.384 51.0: 58.0 0.447 .508 
        H2 ATC 0.319 60.0: 32.0 8.523 .003 
        H3 GCC 0.248 28.0: 48.0 5.277 .022 
        H4 ACT 0.047 9.0: 9.0 
FVLeiden-negative families      
    FGA haplotypes      
        H1 AACT 0.308 55.0: 24.3 11.85 .001 
        H2 GACC 0.281 29.0: 52.0 6.532 .011 
        H3 GATC 0.154 17.0: 22.0 0.64 .423 
        H4 GGCC 0.139 20.0: 20.0 
        H5 GACT 0.105 17.0: 16.7 0.003 .953 
    FGG haplotypes      
        H1 ACC 0.378 37.1: 57.0 4.233 .040 
        H2 ATC 0.315 54.9: 24.0 12.157 .001 
        H3 GCC 0.256 30.9: 36.0 0.38 .537 
        H4 ACT 0.049 6.0: 11.0 1.471 .225 
BlockHaplotype*FrequencyT:U*χ2P
All VT      
    FGA haplotypes      
        H1 AACT 0.324 62.0: 32.6 9.134 .002 
        H2 GACC 0.28 39.7: 51.7 1.576 .209 
        H3 GATC 0.145 17.0: 32.0 4.591 .0321 
        H4 GGCC 0.138 27.3: 23.3 0.317 .574 
        H5 GACT 0.102 19.0: 22.4 0.278 .598 
    FGG haplotypes      
        H1 ACC 0.384 51.0: 58.0 0.447 .508 
        H2 ATC 0.319 60.0: 32.0 8.523 .003 
        H3 GCC 0.248 28.0: 48.0 5.277 .022 
        H4 ACT 0.047 9.0: 9.0 
FVLeiden-negative families      
    FGA haplotypes      
        H1 AACT 0.308 55.0: 24.3 11.85 .001 
        H2 GACC 0.281 29.0: 52.0 6.532 .011 
        H3 GATC 0.154 17.0: 22.0 0.64 .423 
        H4 GGCC 0.139 20.0: 20.0 
        H5 GACT 0.105 17.0: 16.7 0.003 .953 
    FGG haplotypes      
        H1 ACC 0.378 37.1: 57.0 4.233 .040 
        H2 ATC 0.315 54.9: 24.0 12.157 .001 
        H3 GCC 0.256 30.9: 36.0 0.38 .537 
        H4 ACT 0.049 6.0: 11.0 1.471 .225 

T:U indicates ratio of transmissions to nontransmissions.

*

The haplotype association for FVLeiden-positive families is not available because of the small sample size.

The H2-ATC haplotype in FGG is equivalent to H2-GAT haplotype described by Uitte de Willige et al.5  The different annotation is the result of TaqMan primers being designed on the opposite DNA strand.

P value indicates statistical significance.

The strong linkage disequilibrium detected between the FGA-H1 and FGG-H2 risk haplotypes (Figure 2B) raised the possibility that these haplotypes are largely coinherited. Phase-adjusted haplotype analysis showed indeed that a recombination event between FGA-H1 and FGG-H2 had occurred in less than 10% of children.

Replication of association in thromboembolic pediatric stroke

To determine the association of FGA and FGG haplotypes with thromboembolic nonvascular stroke (TS), a corresponding analysis was performed in an independent family-based cohort of 268 nuclear families with TS. In FGA, rs6050 [Thr312Ala] was significantly associated with TS (T:U 95:69, χ2 = 4.122, P = .042). In FGG, rs2066861 showed a nonsignificant trend toward association (T:U 96:73, χ2 = 3.13, P = .076), and rs2066860 was significantly associated with TS (T:U 16:05, χ2 = 5.762, P = .016). For all 3 SNPs, the same allele was overtransmitted to affected offspring as observed in VT. The subsequent haplotype association analysis revealed that haplotype H1 of the FGA gene (AACT) and haplotypes H2 (ATC) and H4 (ACT) of the FGG gene were significantly associated with TS (FGA: H1, T:U 100.7:66.7, χ2 = 6.916, P = .008; FGG: H2, T:U 97:72.4, χ2 = 3.57, P = .05; H4, T:U 5:19, χ2 = 5.671, P = .018), replicating the haplotype association of FGA-H1 and FGG-H2 risk haplotypes, but not the putative protective H3 haplotype (T:U 88.4:88.3, χ2 = 0.00, P = .993).

To increase the statistical power of the study, we examined whether combining the VT and TS study populations would strengthen or weaken the association of this haplotype with thromboembolic disease. Given the allele frequency of 0.41 for the risk allele (eg, rs6050 or rs2066861) and a genotype relative risk of 1.5 and 2.0 for heterozygous and homozygous risk allele carriers, respectively, combining all 512 families from both study samples is predicted to enhance the statistical probability to detect association at an α = 0.05 through TDT analysis to 79.8%. Single-point TDT analysis of the combined pediatric VT and TS study sample documented significant association of genetic variants in FGA and FGG at a level of confidence comparable with (rs2070011, P = .004) or exceeding (rs6050, P = .001; rs2066861, P = .003; rs2066860, P = .018) the level measured in the VT or TS population alone. Importantly, in the corresponding haplotype analysis, the strength of association of the putative risk haplotypes FGA-H1 and FGG-H2 with TS was augmented on pooling the TS and VT population (FGA-H1: P = .001; FGG-H2: P = .002).

This analysis indicates that the VT-risk haplotypes FGA-H1 and FGG-H2 also modify the incidence of TS. Conversely, association analysis of FGG-H3 and FGG-H4 produces divergent outcomes in VT (H3 protective/undertransmitted; H4 neutral) and TS patients (H3 neutral; H4 protective/undertransmitted).

Genetic interaction between FVLeiden and FGA and FGG variants

Consistent with existing data,8  the FVLeiden mutation is significantly associated with VT in our family cohort (T:U 26:13, χ2 = 4.33, P = .037). To detect potentially confounding interactions between genetic variations in FGG and FGA and the FV gene, we investigated whether the observed FGA and FGG haplotype associations with VT were affected by FVLeiden carriership. Therefore, we stratified our cohort on FVLeiden carriership, identifying 46 FVLeiden-positive trios and 198 FVLeiden-negative trios, and repeated the TDT analysis. The association between FGA and FGG and VT was more pronounced in FVLeiden-negative trios (FGA: H1, T:U 55:24, P = .001; FGG: H2, T:U 55:24, P = .001) but was not significant in FVLeiden-positive trios (Tables 1, 2). In addition, the association of FGG-H3 with VT was lost in FVLeiden-negative carriers after stratification.

Because the relatively small number (n = 46) of FVLeiden-positive families may provide insufficient power to detect association, we repeated the analysis in the combined study samples of VT and TS, comprising 420 FVLeiden-negative and 92 FVLeiden-positive families. TDT analysis of the combined study sample (512 families) resulted in a significant association of genetic variants in FGA and FGG in FVLeiden-negative trios, in both single point (FGA: rs6050, T:U 148:99, P = .002; rs2070011, T:U 176:118, P = .001; FGG: rs2066861, T:U 145:105, P = .011; rs2066860, T:U 22:11, P = .05) and haplotype analysis (FGA: H1, P = .001; FGG: H2, P = .007). Single-point TDT in FVLeiden-positive trios showed a trend for association for rs6050 [Thr312Ala] in FGA (T:U 31:19, P = .089) and rs2066861 in FGG (T:U 31:18, P = .063), and a significant association for rs1049636 (T:U 32:12, P = .003). Pooling VT and TS families stratified for FVLeiden status thus strengthened the association of the risk haplotypes FGA-H1 and FGG-H2 in FVLeiden-negative trios but failed to compensate for the loss of association in FVLeiden carriers.

Fibrinogen haplotypes and total fibrinogen and fibrinogen γ′ levels in VT children

Genetic variation in the FGG gene and associated disease risk has been suggested to correlate with plasma concentrations of total fibrinogen, as well as altered absolute and proportional abundance of the fibrinogen γ′ isoform in adult patients with VT or ischemic stroke.2,5,18  To examine how carriership for FGG risk haplotypes correlated with total fibrinogen and γ′ levels in the pediatric VT study population, fibrinogen γ′ levels and total fibrinogen levels were measured in 207 VT children. Total plasma fibrinogen levels were distributed normally, as judged from Kolmogorov-Smirnov testing. Because genotype information for both parents and the affected child was known, individual haplotypes could be assigned to 98% of all children (n = 202). This enabled parametric statistical analysis to investigate the correlation between haplotype status on one hand, and fibrinogen, fibrinogen γ′, and the percentage of fibrinogen γ′ in relation to total fibrinogen, on the other hand.

Total plasma fibrinogen levels were identical in non-H2 carriers (n = 92) and carriers of at least one copy of the FGG-H2 risk haplotype (n = 110; 291.1 ± 87.6 vs 283.0 ± 92.3, P = .26). However, fibrinogen γ′ levels and γ′ content within total fibrinogen (% γ′) were significantly lower in H2 carriers (γ′ levels: 22.7 ± 13.7 vs 26.8 ± 12.0, P = .013; % γ′: 7.63 ± 3.05 vs 9.46 ± 3.17, P = 2.3 × 10−5, Bonferroni-corrected P = .001). This observation was independent of FVLeiden carriership (data not shown). Carriers of at least one copy of the H3 haplotype (n = 82) compared with noncarriers (n = 120) exhibited significantly lower total plasma fibrinogen levels (270.4 ± 109.0 vs 299.1 ± 100.03, P = .012ç Bonferroni-corrected P = not significant), but increased γ′ content within total fibrinogen (% γ′: 9.21 ± 3.09 vs 7.95 ± 3.23, P = .003, Bonferroni-corrected P = .024). These effects were also detected in FVLeiden-negative H3 carriers (fibrinogen: 265.7 ± 69.2 vs 298.1 ± 94.5, P = .009, % γ′: 9.07 ± 3.11 vs 7.79 ± 3.01, P = .005, Bonferroni-corrected P = .038) but did not reach significance in FVLeiden-positive H3 carriers (fibrinogen: 292.6 ± 69.3 vs 302.4 ± 118.9, P = .388; % γ′ content (%): 9.92 ± 3.03 vs 8.52 ± 3.89, P = .125).

Homozygous carriership of the FGG-H2 risk haplotype was associated with the lowest fibrinogen γ′ content, in both absolute and relative terms (Table 3). In compound heterozygous carriers of one H2 allele and any of the other 3 FGG haplotypes, absolute and relative γ′ levels were on average higher than in H2/H2 homozygotes but lower than in non-H2 carriers (Table 3). Homozygous carriers of the (undertransmitted) FGG H3 haplotype show the highest relative fibrinogen γ′ content, in part because of overall lower total fibrinogen levels. A similar positive correlation between FGG-H3 carrier status and relative abundance of γ′ fibrinogen (P = .001, Bonferroni-corrected P = .001) is seen in compound heterozygotes carrying one H3 allele and one H2 allele. Congruent with studies by others,5,19  carriership for any risk haplotype was associated weakly, if at all, with total plasma fibrinogen. These outcomes are consistent with the notion that the VT and TS risk allele FGG-H2 is associated with a lower γ′/total fibrinogen ratio, independent of absolute fibrinogen levels.

Table 3

Correlation of FGG haplotypes with fibrinogen and fibrinogen γ′ content in juvenile VT subjects

HaplotypenFibrinogenγ′ content, %γ′ absolute
H2/H2 26 285.1 ± 70.7 6.01 ± 2.25 17.30 ± 8.00 
H2/H1 48 297.6 ± 107.5 7.67 ± 3.19 23.82 ± 17.21 
H2/H3 30 291.6 ± 67.8 8.99 ± 2.73 26.56 ± 10.80 
H2/H4 293.8 ± 84.3 7.33 ± 2.83 20.56 ± 7.47 
H1/H1 29 316.1 ± 125.9 9.78 ± 2.95 30.76 ± 13.66 
H1/H3 33 253 ± 67.27 9.01 ± 3.89 23.08 ± 19.30 
H1/H4 11 296.0 ± 56.2 9.33 ± 3.60 27.21 ± 9.90 
H3/H3 19 275.6 ± 71.3 9.84 ± 3.15 27.19 ± 10.71 
H3/H4 253 ± 23.1 8.37 ± 4.13 20.61 ± 8.83 
FVLeiden-negative     
    FGG-H2 83 282 ± 72 7.5 ± 3 21.4 ± 11 
    Other 72 279 ± 96 9.2 ± 3.1 25.9 ± 12 
    H2 vs other, P  NS .001 .02 
FVLeiden carrier     
    FGG-H2 21 307 ± 125 7.5 ± 4 23.4 ± 19 
    Other 18 300 ± 75 11 ± 3 32.8 ± 11 
    H2 vs other, P  NS .002 .06 
HaplotypenFibrinogenγ′ content, %γ′ absolute
H2/H2 26 285.1 ± 70.7 6.01 ± 2.25 17.30 ± 8.00 
H2/H1 48 297.6 ± 107.5 7.67 ± 3.19 23.82 ± 17.21 
H2/H3 30 291.6 ± 67.8 8.99 ± 2.73 26.56 ± 10.80 
H2/H4 293.8 ± 84.3 7.33 ± 2.83 20.56 ± 7.47 
H1/H1 29 316.1 ± 125.9 9.78 ± 2.95 30.76 ± 13.66 
H1/H3 33 253 ± 67.27 9.01 ± 3.89 23.08 ± 19.30 
H1/H4 11 296.0 ± 56.2 9.33 ± 3.60 27.21 ± 9.90 
H3/H3 19 275.6 ± 71.3 9.84 ± 3.15 27.19 ± 10.71 
H3/H4 253 ± 23.1 8.37 ± 4.13 20.61 ± 8.83 
FVLeiden-negative     
    FGG-H2 83 282 ± 72 7.5 ± 3 21.4 ± 11 
    Other 72 279 ± 96 9.2 ± 3.1 25.9 ± 12 
    H2 vs other, P  NS .001 .02 
FVLeiden carrier     
    FGG-H2 21 307 ± 125 7.5 ± 4 23.4 ± 19 
    Other 18 300 ± 75 11 ± 3 32.8 ± 11 
    H2 vs other, P  NS .002 .06 

NS indicates not significant.

Results of the current genetic study of 512 families with at least one child affected by childhood-onset VT or TS indicate that carriership for the FGG H2 haplotype is significantly associated with pediatric VT as well as TS. Measurements of total fibrinogen and the γ′ isoform of FGG suggest a gene dose effect of FGG alleles on the γ′:fibrinogen ratio, independent of absolute plasma fibrinogen levels, with highest relative γ′ levels in homozygous FGG-H3 carriers, and lowest relative γ′ levels in children homozygous for the FGG-H2 risk allele. These data are congruent with earlier findings characterizing the FGG H2 allele and associated diminished relative levels of γ′ fibrinogen as a risk factor for VT in adults.5,19  Although a recent case-control study of adults failed to detect an association of the FGG H2 risk haplotype with VT, this lack of association might be ascribed to the relatively small sample size (124 cases and 125 controls) and therefore most probably constitutes a type II error (missed association). The current analysis further detected a statistically significant negative correlation of FGG-H3 carriership with VT. This finding dovetails evidence from one previous study20  that the FGG H3 haplotype may constitute a protective factor for ischemic stroke. We note that, in the original study by Uitte de Willige et al,5  the FGG H3 haplotype was also observed more frequently in controls than in VT patients and was associated with a decreased VT risk (odds ratio = 0.8; 95% confidence interval, 0.6-1.0).

In aggregate, these findings suggest that (1) the plasma γ′/fibrinogen ratio moderately alters the population risk of VT and ischemic stroke and (2) variations in the plasma γ′/fibrinogen ratio are in part determined by genetic variations in the FGG gene, with highest and lowest γ′ ratios associated in a gene dose-dependent manner with the FGG H3 and H2 alleles, respectively.

Our present findings further show that the most frequent FGA-H1 haplotype is overrepresented in pediatric VT patients and in children with nonvascular stroke. In adults, the Ala312Thr polymorphism in FGA has been linked to VT19,21,22  and poststroke mortality in patients with atrial fibrillation.23  The FGA H1 haplotype is uniquely detected by the presence of the A-allele of the SNP rs6050, which encodes the Ala312 variant of the fibrinogen Aα chain, whereas the other 4 major FGA haplotypes are composed of the G-allele of rs6050, encoding the Thr312 Aα chain. Analysis of clots formed from purified fibrinogen Ala312 and Thr312 showed that Ala312 fibrin fibers are thicker, produce clots with reduced elasticity, and exhibit a higher degree of cross-linking mediated by factor XIII.24 

The high degree of linkage disequilibrium between FGG and FGA gene haplotypes confounds the assignment of disease risk to specific alleles and, in general, complicates establishing the association between genetic variations in the fibrinogen gene locus, level, and composition of fibrinogen. Specifically, studies examining the effect of putative FGG H2 risk haplotype associated with diminished γ′ chain production relative to total fibrinogen recognized that this haplotype is in a significant portion of persons coinherited with a second polymorphism located in the FGA gene (FGA Thr312Ala; rs6050). We show that the same is true in our pediatric study population, where the FGA H1 variant is coinherited with the FGG H2 risk haplotype in 188 of 200 children. These observations highlight that FGA-H1 (Ala312) and FGG-H2 (low γ′/γ ratio) are in the majority of persons coinherited. As briefly discussed in 2 previous studies,5,20  this implies, first, that population-based calculations of the risk conferred by these haplotypes must consider haplotype combinations, rather than a model of independent risk factors. Indeed, comparison of patients carrying the combined FGA-H1/FGG-H2 haplotypes (n = 104) versus non-FGA-H1/FGG-H2 carriers (n = 90) yields identical results as obtained from an analysis of the individual haplotype associations with total fibrinogen (287 ± 85 mg/dL vs 283 ± 92, P = not significant), absolute levels of γ′ (21.8 ± 12 vs 27.2 ± 12 mg/dL; P = .002), and γ′/fibrinogen ratio (7.5% ± 3% vs 9.6% ± 3.1%; P = .001).

Recent experiments in mice genetically altered to produce a human γ′ fibrin variant capable of high-affinity interaction with thrombin provided direct experimental evidence that γ′/γA fibrin exerts an anticoagulant effect that ameliorates the prothrombotic effect of the FVLeiden mutation.25  Stratification of families according to FVLeiden carriership showed that the genetic risk attributable to FGA and FGG variants is influenced by the presence or absence of the FVLeiden-mutation: the association of FGG-H2 with a lower γ′/fibrinogen ratio, and with borderline significance (P = .057) also of absolute γ′ levels, was clearly detectable in both FVLeiden-negative and -positive persons and was again independent of total fibrinogen levels (Table 3). The loss of genetic association with disease might be the result of a lack of statistical power to detect a weak association of FGA/FGG haplotypes in the presence of a comparably strong risk factor, such as the FVLeiden mutation. However, a different SNP (rs1039636; data not shown) was associated with VT and/or TS exclusively in FVLeiden carriers, but not in FVLeiden-negative families, indicating that our study was sufficiently powered to detect such positive interactions.

Although the design of the current study inherently does not enable calculations of odds ratios, estimates of the genotype relative risk are consistent with results from population-based association studies that estimate the risk conferred by FGA-H1/FGG-H2 carriership in the range of 1.1 to 1.8. The FGA-H1/FGG-H2 risk alleles therefore only modestly affect overall disease incidence and are in all likelihood not informative for predicting thrombosis risk in a given person. However, genotyping for carriership of the FGA-H1/FGG-H2 alleles could in theory identify a subpopulation of patients whose blood clots exhibit properties distinct from those formed in noncarriers of these alleles. The overall biochemical properties postulated for Ala312 fibrin produced in FGA H1 carriers are remarkably similar to the biochemical effects predicted for diminished levels of γ′ fibrinogen on clot structure, including partial resistance to fibrinolysis,26  enhanced mechanical clot stiffness, and increased fiber diameter. In addition, thrombin bound to the γ′ isoform is relatively resistant to anticoagulant treatment with heparin.27,28  Thus, in vivo formed clots in FGA-H1/FGG-H2 persons might combine, possibly in an exaggerated manner, the properties of clots documented ex vivo for γ′ fibrin or Ala312 fibrin. Fibrin γ′ chains not only interact with thrombin but also contain a nearby binding site for fXIII zymogen. The interaction of fibrin-associated fXIII and thrombin may contribute to the altered clot characteristics of fibrin with a high content of γ′ chains by altering the kinetics of fXIII activation by thrombin.29,30  We note in this context that the fXIII Leu34 variant, which has been identified as a protective trait in thrombotic disorders, produces similar alterations in fibrin structure as high levels of γ′ fibrin.29  In vitro experiments with purified fibrinogen suggest that an increased rate of thrombin generation, as probably occurs in FVLeiden carriers, may override the biochemical differences between the structures of Ala312 and Thr312 fibrin, or γA/γA and γ′/γA fibrin,31,,34  providing a theoretical explanation how the FVLeiden mutation might mitigate the risk conferred by FGA-H1/FGG-H2.

Taken together, the effects of polymorphisms in fXIII, fibrinogen A, and fibrinogen γ chain genes on thrombosis may converge on a common biochemical pathway that defines fibrin structure and susceptibility of formed fibrin to fibrinolysis. The broader significance of these findings for identifying patients at risk and the therapeutic approach to thrombosis remain to be investigated.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.

Contribution: T. Seehafer, S.T., and T. Schulte conducted the genotyping and data management; H.W. and I.H. performed the biochemical studies on fibrinogen gamma′ variants; and M.S. and U.N.-G. were responsible for the statistical analyses. All authors had full access to the data and took part in the design, execution, and data analysis, and in writing the report.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Monika Stoll, Genetic Epidemiology of Vascular Disorders, Leibniz-Institute for Arteriosclerosis Research, Domagkstrasse 3, 48149 Muenster, Germany; e-mail: [email protected].

1
Koster
T
Rosendaal
FR
Reitsma
PH
van der Velden
PA
Briet
E
Vandenbroucke
JP
Factor VII and fibrinogen levels as risk factors for venous thrombosis: a case-control study of plasma levels and DNA polymorphisms—the Leiden Thrombophilia Study (LETS).
Thromb Haemost
1994
71
719
722
2
Van Hylckama Vlieg
A
Callas
PW
Cushman
M
Bertina
RM
Rosendaal
FR
Inter-relation of coagulation factors and d-dimer levels in healthy individuals.
J Thromb Haemost
2003
1
516
522
3
Lane
DA
Grant
PJ
Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease.
Blood
2000
95
1517
1532
4
Kardys
I
Uitterlinden
AG
Hofman
A
Witteman
JC
de Maat
MP
Fibrinogen gene haplotypes in relation to risk of coronary events and coronary and extracoronary atherosclerosis: the Rotterdam Study.
Thromb Haemost
2007
97
288
295
5
Uitte de Willige
S
de Visser
MC
Houwing-Duistermaat
JJ
Rosendaal
FR
Vos
HL
Bertina
RM
Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma′ levels.
Blood
2005
106
4176
4183
6
Grünbacher
G
Weger
W
Marx-Neuhold
E
et al
The fibrinogen gamma (FGG) 10034C>T polymorphism is associated with venous thrombosis.
Thromb Res
2007
121
33
36
7
Young
G
Albisetti
M
Bonduel
M
et al
Impact of inherited thrombophilia on venous thromboembolism in children: a systematic review and meta-analysis of observational studies.
Circulation
2008
118
1373
1382
8
Nowak-Göttl
U
Kurnik
K
Krumpel
A
Stoll
M
Thrombophilia in the young.
Hamostaseologie
2008
28
16
20
9
Caruso
V
Iacoviello
L
Di Castelnuovo
A
et al
Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients.
Blood
2006
108
2216
2222
10
Haywood
S
Liesner
R
Pindora
S
Ganesan
V
Thrombophilia and first arterial ischaemic stroke: a systematic review.
Arch Dis Child
2005
90
402
405
11
Sträter
R
Becker
S
von Eckardstein
A
et al
Prospective assessment of risk factors for recurrent stroke during childhood: a 5-year follow-up study.
Lancet
2002
360
1540
1545
12
Nowak-Göttl
U
Langer
C
Bergs
S
Thedieck
S
Strater
R
Stoll
M
Genetics of hemostasis: differential effects of heritability and household components influencing lipid concentrations and clotting factor levels in 282 pediatric stroke families.
Environ Health Perspect
2008
116
839
843
13
Mosesson
MW
Hernandez
I
Raife
TJ
et al
Plasma fibrinogen gamma′ chain content in the thrombotic microangiopathy syndrome.
J Thromb Haemost
2007
5
62
69
14
Barrett
JC
Fry
B
Maller
J
Daly
MJ
Haploview: analysis and visualization of LD and haplotype maps.
Bioinformatics
2005
21
263
265
15
Junker
R
Koch
HG
Auberger
K
Munchow
N
Ehrenforth
S
Nowak-Gottl
U
Prothrombin G20210A gene mutation and further prothrombotic risk factors in childhood thrombophilia.
Arterioscler Thromb Vasc Biol
1999
19
2568
2572
16
Nowak-Göttl
U
Sträter
R
Heinecke
A
et al
Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood.
Blood
1999
94
3678
3682
17
Spielman
RS
McGinnis
RE
Ewens
WJ
Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM).
Am J Hum Genet
1993
52
506
516
18
Jood
K
Danielson
J
Ladenvall
C
Blomstrand
C
Jern
C
Fibrinogen gene variation and ischemic stroke.
J Thromb Haemost
2008
6
897
904
19
Carter
AM
Catto
AJ
Kohler
HP
Ariens
RA
Stickland
MH
Grant
PJ
alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolism.
Blood
2000
96
1177
1179
20
Cheung
EY
Uitte de Willige
S
Vos
HL
et al
Fibrinogen gamma′ in ischemic stroke: a case-control study.
Stroke
2008
39
1033
1035
21
Rasmussen-Torvik
LJ
Cushman
M
Tsai
MY
et al
The association of alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolism in the LITE study.
Thromb Res
2007
121
1
7
22
Le Gal
G
Delahousse
B
Lacut
K
et al
Fibrinogen Aalpha-Thr312Ala and factor XIII-A Val34Leu polymorphisms in idiopathic venous thromboembolism.
Thromb Res
2007
121
333
338
23
Carter
AM
Catto
AJ
Grant
PJ
Association of the alpha-fibrinogen Thr312Ala polymorphism with poststroke mortality in subjects with atrial fibrillation.
Circulation
1999
99
2423
2426
24
Standeven
KF
Grant
PJ
Carter
AM
Scheiner
T
Weisel
JW
Ariens
RA
Functional analysis of the fibrinogen Aalpha Thr312Ala polymorphism: effects on fibrin structure and function.
Circulation
2003
107
2326
2330
25
Mosesson
MW
Cooley
BC
Hernandez
I
Diorio
JP
Weiler
H
Thrombosis risk modification in transgenic mice containing the human fibrinogen thrombin-binding gamma′ chain sequence.
J Thromb Haemost
2009
7
102
110
26
Falls
LA
Farrell
DH
Resistance of gammaA/gamma′ fibrin clots to fibrinolysis.
J Biol Chem
1997
272
14251
14256
27
Lovely
RS
Moaddel
M
Farrell
DH
Fibrinogen gamma′ chain binds thrombin exosite II.
J Thromb Haemost
2003
1
124
131
28
Fredenburgh
JC
Stafford
AR
Leslie
BA
Weitz
JI
Bivalent binding to gammaA/gamma′-fibrin engages both exosites of thrombin and protects it from inhibition by the antithrombin-heparin complex.
J Biol Chem
2008
283
2470
2477
29
Ariens
RA
Lai
TS
Weisel
JW
Greenberg
CS
Grant
PJ
Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms.
Blood
2002
100
743
754
30
Mosesson
MW
Update on antithrombin I (fibrin).
Thromb Haemost
2007
98
105
108
31
Campbell
RA
Overmyer
KA
Bagnell
CR
Wolberg
AS
Cellular procoagulant activity dictates clot structure and stability as a function of distance from the cell surface.
Arterioscler Thromb Vasc Biol
2008
28
2247
2254
32
Wolberg
AS
Thrombin generation and fibrin clot structure.
Blood Rev
2007
21
131
142
33
Wolberg
AS
Allen
GA
Monroe
DM
Hedner
U
Roberts
HR
Hoffman
M
High dose factor VIIa improves clot structure and stability in a model of haemophilia B.
Br J Haematol
2005
131
645
655
34
Wolberg
AS
Monroe
DM
Roberts
HR
Hoffman
M
Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk.
Blood
2003
1001
3008
3013
Sign in via your Institution